

17th March, 2022

The Dy. General Manager (Listing Dept.)
BSE Limited,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: Torrent Pharma enters into licensing agreement with Medicine Patent Pool to manufacture and commercialise generic version of Pfizer Oral COVID-19 Treatment

A press release issued by the Company with respect to captioned subject is attached for your information and record.

Thanking you,

Yours sincerely,

For TORRENT PHARMACEUTICALS LIMITED



MAHESH AGRAWAL
VP (LEGAL) & COMPANY SECRETARY

Encl : A/a

Torrent Pharma enters into licensing agreement with Medicine Patent Pool to manufacture and commercialise generic version of Pfizer Oral COVID-19 Treatment

Torrent Pharmaceuticals Limited (herein after referred to as “TPL”) has announced that it has signed a non-exclusive, non-transferable, non-sub licensable, license agreement to use the patents and know-how in relation to the compound nirmatrelvir with Medicine Patent Pool (herein after referred to as “MPP”) for manufacture and commercialisation of the generic version of PAXLOVID™ [product containing the compound nirmatrelvir (PF-07321332) to be co-packaged and co-administered with ritonavir] in 95 low and middle income countries including India for treatment and/or prevention of COVID-19 caused by SARS-CoV-2.

Earlier, MPP had entered into license agreement with PF Prism Holdings B.V. (Pfizer) granting MPP with the rights to sub-license manufacture and commercialisation rights to sub-licensees.

The oral COVID-19 treatment comprises of nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating and ritonavir, which slows down nirmatrelvir’s breakdown to help it remain in the body for a longer period at higher concentrations.

TPL will launch the product after obtaining necessary approval from Regulatory Agencies.

Pfizer markets its oral COVID-19 treatment under the name PAXLOVID™, which is authorized by U.S. Food and Drug Administration (FDA) [for Emergency Use Authorisation (EUA)] and the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of COVID-19 in patients at high-risk of progressing to serious illness.

Commenting on the arrangement, Aman Mehta (Executive Director) said: “We are pleased to enter into this agreement with MPP and is part of our continued endeavor to make Covid treatments as accessible as possible to patients.”

About Torrent Pharmaceuticals Ltd:

Torrent Pharma, with annual revenues of more than Rs. 8,000 crores, is the flagship Company of the Torrent Group, with group revenues of more than Rs. 20,000 crores. It is ranked 8th in the Indian Pharmaceuticals Market and is amongst the Top 5 in the therapeutics segments of Cardiovascular (CV), Gastro Intestinal (GI), Central Nervous System (CNS), and Vitamins Minerals Nutritionals (VMN).

It is a specialty-focused company with 75%+ of its revenue in India from chronic & subchronic therapies. It has presence in 40 countries and is ranked No. 1 amongst the Indian pharma Companies in Brazil, Germany and Philippines. Torrent has 8 manufacturing facilities (7 in India & 1 in US), of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing approximately 750+ scientists.

In case of any enquiry / clarification, please contact Mr. Jayesh Desai on +91 9824501396

TORRENT PHARMACEUTICALS LIMITED

CIN : L24230GJ1972PLC002126

Reg. Office : Torrent House, Off Ashram Road, Ahmedabad - 380 009, India. Phone : +91 79 26599000, Fax : +91 79 26582100, www.torrentpharma.com